0001012975-14-000649.txt : 20141002
0001012975-14-000649.hdr.sgml : 20141002
20141002174307
ACCESSION NUMBER: 0001012975-14-000649
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140930
FILED AS OF DATE: 20141002
DATE AS OF CHANGE: 20141002
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILLIS STEVEN
CENTRAL INDEX KEY: 0001229592
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 141137705
MAIL ADDRESS:
STREET 1: 1000 SECOND AVENUE
STREET 2: SUITE 3700
CITY: SEATTLE
STATE: WA
ZIP: 98104
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2014-09-30
0001293971
bluebird bio, Inc.
BLUE
0001229592
GILLIS STEVEN
C/O ARCH VENTURE PARTNERS
8725 WEST HIGGINS ROAD, SUITE 290
CHICAGO
IL
60631
1
0
0
0
Common Stock
2014-09-30
4
S
0
32095
36.08
D
1272616
I
By ARCH Venture Fund VII, L.P.
Common Stock
2014-10-01
4
S
0
11516
34.75
D
1261100
I
By ARCH Venture Fund VII, L.P.
Common Stock
2014-10-02
4
S
0
47554
34.87
D
1213546
I
By ARCH Venture Fund VII, L.P.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.315, inclusive. The reporting person undertakes to provide to BLUE, any security holder of BLUE, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.75 to $34.795, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.75 to $35.03, inclusive.
These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own Fund shares held by ARCH Fund VII. Each Managing Director disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Managing Directors are the beneficial owners of such securities for Section 16 or any other purpose.
Steven Gillis owns an interest in ARCH Partners VII but does not have voting or investment control over the shares held by ARCH Fund VII and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that Steven Gillis is the beneficial owner of such securities for Section 16 or any other purpose.
/s/ Steven Gillis
2014-10-02